Skip to main content
      #1726 IA from immune checkpoint inhibitors (ICI) is a distinct autoimmune entity: T cell-driven but not antibody-mediate

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #1726 IA from immune checkpoint inhibitors (ICI) is a distinct autoimmune entity: T cell-driven but not antibody-mediated irAE arthritis shows hyperactive, cytotoxic CD8+ T cells & metabolic reprogramming, unlike RA. IL-6, IL-12 & IFNα fuel this process. @RheumNow #ACR25
      #ClinicalPearl

      #seroneg #arthritis often has
      👇
      #involvement of
      1st toe IP joint

      Look at the feet 🦶

      @RheumNow

      Janet Pope Janetbirdope

      1 week 2 days ago
      #ClinicalPearl #seroneg #arthritis often has 👇 #involvement of 1st toe IP joint Look at the feet 🦶 @RheumNow @ACRheum #ACR25 #28T08 Session secrets &pearls Tues https://t.co/EfqkLsTKmt
      Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretab

      Antoni Chan MD (Prof) synovialjoints

      1 week 2 days ago
      Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretability. Think of using and validating AI in the same way we train our residents. The human interface still needed @RheumNow #ACR25 https://t.co/TYKud057ag
      #1725 Functional NOTCH4 variants contribute to vasculopathy & fibrosis in SSc, particularly in African-American pati

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #1725 Functional NOTCH4 variants contribute to vasculopathy & fibrosis in SSc, particularly in African-American patients NOTCH4 hyperactivation disrupts angiogenesis & drives EndoMT; inhibition (including with FDA-approved Nirogacestat) restores vascular repair @RheumNow #ACR25
      #1724 MAIT cells central in RA pathogenesis. These innate-like T cells accumulate in synovial fluid, driving fibroblast

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #1724 MAIT cells central in RA pathogenesis. These innate-like T cells accumulate in synovial fluid, driving fibroblast activation, cytokine release & joint damage. Blocking MAIT activation or deleting MR1 reduces arthritis in mice- a potential new target in RA. @RheumNow #ACR25
      The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D

      More on T Cell engagers , this time with ga

      Nouf Al hemmadi NoufAhmedAlham2

      1 week 2 days ago
      The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D More on T Cell engagers , this time with gama delta T cell ( tiny but mighty ). Kate Roslin talks about advantages of this protocol. (No cytokines thus less toxicity). @Yuz6Yusof @RheumNow #ACR25
      Pooled data fr diff SLE cohorts by Dr SGarg et al were evaluated to determine an upper threshold tx range of HCQ

      750-1

      sheila RHEUMarampa

      1 week 2 days ago
      Pooled data fr diff SLE cohorts by Dr SGarg et al were evaluated to determine an upper threshold tx range of HCQ 750-1150 ng/mL: safe & effective HCQ levels >1150ng/mL-supratx, no added tx benefit CKD st >/=3: 2x ⬆️odds of toxic hcq levels #ACR25 @RheumNow Abs1722 #ACRBest https://t.co/RFx1VO0bov
      #1723 Why is systemic autoimmunity more common in females?
      Loss of X-chromosome inactivation maintenance in B cells (not

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #1723 Why is systemic autoimmunity more common in females? Loss of X-chromosome inactivation maintenance in B cells (not T cells) amplifies interferon-driven disease, with increased autoantibodies, inflammation and renal injury. Key mechanistic advance. @RheumNow #ACR25
      3rd plenary session!

      #1722 Defining safe HCQ levels in SLE: whole-blood 750-1150ng/mL= therapeutic range; >1150ng/mL

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      3rd plenary session! #1722 Defining safe HCQ levels in SLE: whole-blood 750-1150ng/mL= therapeutic range; >1150ng/mL ➡️ ~2× toxicity risk; <750ng/mL ➡️ higher flare risk CKD ≥3 increases odds of supratherapeutic levels New era of precision monitoring in SLE? @RheumNow #ACR25
      Plenary 3, HCQ blood levels in SLE

      HCQ level > 1150: 1.9x risk of HCQ toxicity
      HCQ level < 750: 1.4x risk of act

      Mike Putman EBRheum

      1 week 2 days ago
      Plenary 3, HCQ blood levels in SLE HCQ level > 1150: 1.9x risk of HCQ toxicity HCQ level < 750: 1.4x risk of active SLE HCQ dose < 5mg/kg: 1.9x risk active SLE My take home? Blindly reducing dose to <5mg/kg is BAD; use levels instead! @RheumNow #ACRBest #ACR25 Abstr1722 https://t.co/UCBPAKAyon
      Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN

      The amazing @Janetbirdope discussing head to head trial

      Nouf Al hemmadi NoufAhmedAlham2

      1 week 2 days ago
      Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN The amazing @Janetbirdope discussing head to head trials in Axial SpA and PsA with primary failure to TNF. To switch to another TNF or IL17? IL17 for my PsA patient for sure. @RheumNow #ACR25
      #ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development w

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 2 days ago
      #ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5
      Two new studies presented this year tackle a key question: can our initial treatment choices influence who ends up in the difficult-to-treat category?
      Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.
      New Paradigms in RA Treatment
      ×